Novavax, Inc. (NVAX) vs Taysha Gene Therapies, Inc. (TSHA)
- Novavax, Inc. NVAX 7.95 −1.36%
- Taysha Gene Therapies, Inc. TSHA 4.01 −1.23%
Novavax, Inc. and Taysha Gene Therapies, Inc. are both Biotechnology companies. Novavax, Inc. and Taysha Gene Therapies, Inc. are of similar size ($1.3B and $1.3B). Taysha Gene Therapies, Inc. grew revenue faster over the last twelve months: 19.0% against −61.3%. Taysha Gene Therapies, Inc. has the higher net margin (0.00% vs −18.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Novavax, Inc. leads on 8 and Taysha Gene Therapies, Inc. on 7.
Valuation
Profitability
| Metric | NVAX | TSHA | Biotechnology median |
|---|---|---|---|
| Gross margin | 78.01% | 100.00% | 70.18% |
| Operating margin | (21.23%) | 0.00% | 0.00% |
| Net margin | (18.64%) | 0.00% | 0.00% |
| Free cash flow margin | (59.25%) | 0.00% | 0.00% |
| Return on equity | 41.08% | (54.18%) | (50.72%) |
| Return on assets | (7.42%) | (41.52%) | (45.56%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack